Exhibit 99.Section 19(a)
EXHIBIT 3: SECTION 19(a) NOTICE TO FUND’S SHAREHOLDERS
TEKLA LIFE SCIENCES INVESTORS
Notification of Sources of Distribution
Distribution Paid Date: December 31, 2019
Distribution Amount Per Common Share: $0.33
The following table sets forth the estimated amounts of the current distribution, paid December 31, 2019, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, and return of capital or other capital source.
| | | Current
Distribution | | | Percentage
Breakdown
of Current
Distributions | | | Total Cumulative
Distributions for the
Fiscal Year to Date1 | | |
Percentage
Breakdown of the
Total Cumulative
Distributions for the
Fiscal Year to Date1 | |
| Net Investment Income | | $ | 0.0000 | | | | 0 | % | | $ | 0.0000 | | | | 0 | % |
| Net Realized ST Cap Gains | | $ | 0.0000 | | | | 0 | % | | $ | 0.0000 | | | | 0 | % |
| Net Realized LT Cap Gains | | $ | 0.3300 | | | | 100 | % | | $ | 0.3300 | | | | 100 | % |
| Return of Capital or Other Capital Source | | $ | 0.0000 | | | | 0 | % | | $ | 0.0000 | | | | 0 | % |
| TOTAL (per common share): | | $ | 0.3300 | | | | 100 | % | | $ | 0.3300 | | | | 100 | % |
The table below includes information relating to the Fund’s performance based on its NAV for certain periods.
| Average annual total return at NAV for the period from October 31, 2014 through October 31, 2019 | | | 2.51 | % |
| Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2019 | | | 7.42 | % |
| Cumulative total return at NAV for the fiscal year, through October 31, 20192 | | | 7.49 | % |
| Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of October 31, 20191 | | | 1.85 | % |
You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.
The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $108,031,990, of which $95,389,385 represents net unrealized appreciation of portfolio securities.
The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
1The Fund’s current fiscal year began on October 1, 2019.
2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2019 through October 31, 2019.
Tekla Life Sciences Investors
CUSIP: 87911K100
www.teklacap.com
Tekla Capital Management LLC
100 Federal Street, 19th Floor
Boston, Massachusetts 02110
617-772-8500 Fax: 617-772-8577
03632B 002CSNA638
TEKLA LIFE SCIENCES INVESTORS
Notification of Sources of Distribution
Distribution Paid Date: March 31, 2020
Distribution Amount Per Common Share: $0.39
The following table sets forth the estimated amounts of the current distribution, paid March 31, 2020, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, and return of capital or other capital source.
| | | Current
Distribution | | | Percentage Breakdown
of Current
Distributions | | | Total Cumulative
Distributions for the
Fiscal Year to Date1 | | |
Percentage
Breakdown of the
Total Cumulative
Distributions for the
Fiscal Year to Date1 | |
| Net Investment Income | | $ | 0.0000 | | | | 0 | % | | $ | 0.0000 | | | | 0 | % |
| Net Realized ST Cap Gains | | $ | 0.0000 | | | | 0 | % | | $ | 0.0000 | | | | 0 | % |
| Net Realized LT Cap Gains | | $ | 0.3900 | | | | 100 | % | | $ | 0.7200 | | | | 100 | % |
| Return of Capital or Other Capital Source | | $ | 0.0000 | | | | 0 | % | | $ | 0.0000 | | | | 0 | % |
| TOTAL (per common share): | | $ | 0.3900 | | | | 100 | % | | $ | 0.7200 | | | | 100 | % |
The table below includes information relating to the Fund’s performance based on its NAV for certain periods.
| Average annual total return at NAV for the period from January 31, 2015 through January 31, 2020 | | | 2.47 | % |
| Annualized current distribution rate expressed as a percentage of NAV as of January 31, 2020 | | | 8.46 | % |
| Cumulative total return at NAV for the fiscal year, through January 31, 20202 | | | 13.48 | % |
| Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of January 31, 20201 | | | 3.90 | % |
You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.
The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $29,547,773, of which $10,156,073 represents net unrealized appreciation of portfolio securities.
The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
1The Fund’s current fiscal year began on October 1, 2019.
2Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2019 through January 31, 2020.
Tekla Life Sciences Investors
CUSIP: 87911K100
www.teklacap.com
Tekla Capital Management LLC
100 Federal Street, 19th Floor
Boston, Massachusetts 02110
617-772-8500 Fax: 617-772-8577
038F7A 002CSNAA51
